DOCSLIB.ORG

Evidence Dossier

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Evidence Dossier CONFIDENTIAL Evidence Dossier PUBLISH DATE January 22, 2021 National Comprehensive Cancer Network® (NCCN) makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. US-FLDX-2000011 Jump to Table of Contents Last update: January 22, 2021 1 EXECUTIVE SUMMARY In August 2020, FoundationOne® Liquid CDx became the broadest United States (US) Food and Drug Administration (FDA)-approved circulating tumor deoxyribonucleic acid (ctDNA)-based comprehensive genomic profiling (CGP) assay (liquid biopsy) for use as a companion diagnostic to identify patients who may benefit from treatment with certain targeted therapies in accordance with the approved therapeutic product labeling. FoundationOne Liquid CDx is currently an FDA-approved companion diagnostic for 7 drug therapies in 4 cancer types.1 Additionally, FoundationOne Liquid CDx is intended to provide tumor mutation profiling to be used by qualified healthcare professionals in accordance with professional guidelines in oncology for patients with malignant neoplasms (FoundationOne Liquid CDx Test Description). FoundationOne Liquid CDx is the new liquid biopsy test that replaces the previously available liquid biopsy laboratory developed test (LDT), FoundationOne Liquid (Table 6-4). FoundationOne Liquid CDx is part of a portfolio of CGP assays that provides a CGP testing option for any advanced cancer patient (Figure 1-1). Figure 1-1. Foundation Medicine Portfolio Abbreviations: DNA, deoxyribonucleic acid; NY, New York; FDA, Food and Drug Administration; RNA, ribonucleic acid. Source: Foundation Medicine, Inc. Identifying Appropriate Treatment Options in Advanced Cancer Represents Significant Unmet Need Approximately 540,000 people are diagnosed with advanced cancer annually in the US (Figure 1-2) (Epidemiology of Advanced Cancer).2,3,4 Prognosis remains poor for most types of metastatic solid CONFIDENTIAL PAGE 2 Jump to Table of Contents Last update: January 22, 2021 tumors, with relatively low 5-year survival, ranging from 5% in patients with non-small cell lung cancer (NSCLC) to 39% in patients with head and neck cancer (Historical Treatment of Advanced Cancer).5,6 Figure 1-2. Estimated 2020 Distribution of Stage of Disease Within the Select Solid Tumor Cancers 350,000 300,000 250,000 200,000 150,000 100,000 50,000 0 Breast Melanoma Prostate NSCLC Pancreas Hepatobiliarya Ovarian Stage III or IV All stages a Hepatobiliary only includes HCC for this calculation. Abbreviations: HCC, hepatocellular carcinoma; NSCLC, non-small cell lung cancer. Source: Kantar Health 2020.4 Avoidance of therapies that are unlikely to benefit patients and potentially have serious side effects will maximize patient outcomes and reduce costs (Historical Treatment of Advanced Cancer).7-9 . Response rates (RRs) to chemotherapy, the historical standard of care, are typically poor among patients with advanced cancer, with complete responses (CRs) observed in 10% or fewer patients.10 . Further, chemotherapy-related adverse events result in hospitalization in up to 20% of advanced cancer patients.7-9 . The goal is to provide patients with therapies that have a potential to provide benefit, and although all therapies have toxicities, the benefit:risk ratio, is of utmost importance when making therapeutic decisions for patients.8 A precision medicine approach can have advantages over cytotoxic regimens. The use of biomarker-based targeted therapy has been shown to improve treatment response and survival outcomes in patients with actionable alterations for which there is targeted therapy available (either FDA approved or in clinical trials) as compared with standard of care chemotherapy or best supportive care (BSC) (Figure 1-3) (Molecularly Matched Therapies Improve Clinical Outcomes).11-13 CONFIDENTIAL PAGE 3 Jump to Table of Contents Last update: January 22, 2021 Figure 1-3. Response Rates (A) and Survival (B) With Genomically Matched Therapy vs Nonmatched Therapy Across Tumor Types 35 A 31 B 30 25 20 15 10 5 Overall Respone% Rate, 5 0 Matched therapy Nonmatched therapy a Meta-analysis comparing patient outcomes from phase 1 studies that used a biomarker-based selection strategy vs those that did not. Source: Schwaederle 2016.13 b Prospective study comparing patients who received genomically matched therapy vs those who received unmatched therapy. Source: Kopetz 2019.14 Abbreviations: CI, confidence interval; HR, hazard ratio. However, the growing complexity of advanced cancer treatment is associated with significant drug spend. Costs to treat advanced cancer are generally at least 2-fold higher than for earlier-stage disease.15-18 . The recent surge in new treatment options (and the resulting increasing numbers of cancer being treated with available medicines and for longer) is a key driver in spending and growth rates.19-21 It is essential to appropriately select patients for treatment with targeted and immunotherapies. The majority of cancer types have ≥1 targetable biomarker; despite this, generally fewer than 50% of patients receive molecular testing (Real-World Molecular Testing Patterns).22-27 . The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for NSCLC recommend molecular testing and state that broad molecular profiling is a key component in improving the care of patients with metastatic NSCLC.28 Further, the NCCN Guidelines® for NSCLC, Prostate Cancer, Breast Cancer, Melanoma: Cutaneous, and Ovarian Cancer including Fallopian Tube Cancer and Primary Peritoneal Cancer include molecular testing recommendations for all eligible patients with metastatic disease (Guideline Recommendations for Molecular Testing).29-33 . In addition to the many targeted therapies and immunotherapy agents now available, the NCCN Guidelines state that the best management of any patient with cancer is in a clinical trial;29-35 approximately 40% of clinical trials utilize the presence of tumor genomic alterations or biomarkers for eligibility and/or stratification (Guideline Recommendations for Molecular Testing).21 CONFIDENTIAL PAGE 4 Jump to Table of Contents Last update: January 22, 2021 A CGP Approach to Testing Optimizes Treatment Selection As the field of molecular profiling is rapidly evolving, there is a shift in focus from a few small, predictive, disease-specific tests to a broader panel testing that can analyze changes in a myriad of genes or gene products (Evidence of Improved Detection of Genomic Alterations With CGP).34 Overall, CGP testing provides valuable information on the presence of actionable biomarkers, which enables healthcare providers to make evidence-based treatment decisions regarding treatments that result in improved outcomes for patients with advanced cancer (Decision Impact of CGP in Clinical Practice).13,31,32 . CGP utilizes next-generation sequencing (NGS) technology to examine entire regions of cancer- relevant genes (in contrast to limited “hotspot” tests) and genes in established cancer pathways for all tumor types, identifying the 4 main classes of genomic alterations (base substitutions, insertions or deletions, copy number alterations [CNAs], gene rearrangements) and reporting complex biomarkers such as tumor mutational burden (TMB) and microsatellite instability (MSI), to inform cancer treatment decisions via a single assay.30,34,36-38 . Results from CGP can provide information about genomic alteration to guide uses of FDA- approved targeted therapies, and potential eligibility for oncology clinical trials, and information that enables physicians to use chemotherapy more effectively (Decision Impact of CGP in Clinical Practice).14,21,39,40 CGP Allows for Improved Detection of Genomic Alterations . Of patients with advanced cancer who undergo CGP, 51.7% to 99% will have an actionable alteration that can be matched to either a targeted therapy or to a genomically matched clinical trial.11,14,29,39,41-52 . In patients who previously underwent conventional testing methods (ie, fluorescence in situ hybridization [FISH], polymerase chain reaction [PCR], single-gene tests, and hotspot testing), CGP identified at least 1 actionable genomic alteration not previously identified in up to 84% across multiple tumor types (Evidence of Improved Detection of Genomic Alterations With CGP).14,47 . Further, CGP has been shown to improve detection of genomic alterations within specific tumor types (Table 1-1).53-56 Table 1-1. Detection of More Patients With Actionable Genomic Alterations With CGP in Specific Tumor Types Melanoma CGP can identify up to 37% more patients with BRAF alterations compared (Boussemart 2019)53 with traditional PCR-based methods53 Colorectal cancer (CRC) Of the 6.4% of patients who harbor potentially resistant KRAS mutations outside (Rankin 2016)54 of codons 12 and 13, CGP may be able to identify 88% of those resistance alterations not assessed by focused PCR-based testing54 Breast cancer CGP can identify patients who harbor multiple PIK3CA mutations that are 55 55 (Vasan 2019) traditionally missed by hotspot testing CONFIDENTIAL PAGE 5 Jump to Table of Contents Last update: January 22, 2021 NSCLC CGP has been shown to identify up to 35% more patients with ALK fusions (Rozenblum 2017)56 and 21% more patients with EGFR alterationsa compared with traditional methods in NSCLC56 a 41% of these EGFR mutations are common alterations targetable by an FDA-approved therapy in the patient’s tumor type. Abbreviations: ALK, anaplastic lymphoma kinase; BRAF, v-raf murine sarcoma
Load more

Recommended publications
  • Australian Public Assessment Report for Larotrectinib
    Australian Public Assessment Report for Larotrectinib Proprietary Product Name: Vitrakvi Sponsor: Bayer Australia Limited December 2020 Therapeutic Goods Administration About the Therapeutic Goods Administration (TGA) • The Therapeutic Goods Administration (TGA) is part of the Australian Government Department of Health and is responsible for regulating medicines and medical devices. • The TGA administers the Therapeutic Goods Act 1989 (the Act), applying a risk management approach designed to ensure therapeutic goods supplied in Australia meet acceptable standards of quality, safety and efficacy (performance) when necessary. • The work of the TGA is based on applying scientific and clinical expertise to decision- making, to ensure that the benefits to consumers outweigh any risks associated with the use of medicines and medical devices. • The TGA relies on the public, healthcare professionals and industry to report problems with medicines or medical devices. TGA investigates reports received by it to determine any necessary regulatory action. • To report a problem with a medicine or medical device, please see the information on the TGA website <https://www.tga.gov.au>. About AusPARs • An Australian Public Assessment Report (AusPAR) provides information about the evaluation of a prescription medicine and the considerations that led the TGA to approve or not approve a prescription medicine submission. • AusPARs are prepared and published by the TGA. • An AusPAR is prepared for submissions that relate to new chemical entities, generic medicines, major variations and extensions of indications. • An AusPAR is a static document; it provides information that relates to a submission at a particular point in time. • A new AusPAR will be developed to reflect changes to indications and/or major variations to a prescription medicine subject to evaluation by the TGA.
    [Show full text]
  • Entrectinib (Interim Monograph)
    Entrectinib (interim monograph) DRUG NAME: Entrectinib SYNONYM(S): RXDX-1011, NMS-E6282 COMMON TRADE NAME(S): ROZLYTREK® CLASSIFICATION: molecular targeted therapy Special pediatric considerations are noted when applicable, otherwise adult provisions apply. MECHANISM OF ACTION: Entrectinib is an orally administered, small molecule, multi-target tyrosine kinase inhibitor which targets tropomyosin- related kinase (Trk) proteins TrkA, TrkB, and TrkC, proto-oncogene tyrosine-protein kinase ROS (ROS1) and anaplastic lymphoma kinase (ALK). TrkA, TrkB, and TrkC are receptor tyrosine kinases encoded by the neurotrophic tyrosine receptor kinase (NTRK) genes NTRK1, NTRK2, and NTRK3, respectively. Fusion proteins that include Trk, ROS1, or ALK kinase domains drive tumorigenic potential through hyperactivation of downstream signalling pathways leading to unconstrained cell proliferation. By potently inhibiting the Trk kinases, ROS1, and ALK, entrectinib inhibits downstream signalling pathways, cell proliferation and induces tumour cell apoptosis.3-5 PHARMACOKINETICS: Oral Absorption bioavailability = 55%; Tmax = 4-6 hours; Tmax delayed 2 h by high-fat, high-calorie food intake Distribution highly bound to human plasma proteins cross blood brain barrier? yes volume of distribution 551 L (entrectinib); 81.1 L (M5) plasma protein binding >99% (entrectinib and M5) Metabolism primarily metabolized by CYP 3A4 active metabolite(s) M5 inactive metabolite(s) M11 Excretion primarily via hepatic clearance urine 3.06% feces 82.9% (36% as unchanged entrectinib, 22% as M5) terminal half life 20 h (entrectinib); 40 h (M5) clearance 19.6 L/h (entrectinib); 52.4 L/h (M5) Elderly no clinically significant difference Children comparable pharmacokinetics of entrectinib and M5 in adults and children Ethnicity no clinically significant difference Adapted from standard reference3,4 unless specified otherwise.
    [Show full text]
  • Cognition and Steroidogenesis in the Rhesus Macaque
    Cognition and Steroidogenesis in the Rhesus Macaque Krystina G Sorwell A DISSERTATION Presented to the Department of Behavioral Neuroscience and the Oregon Health & Science University School of Medicine in partial fulfillment of the requirements for the degree of Doctor of Philosophy November 2013 School of Medicine Oregon Health & Science University CERTIFICATE OF APPROVAL This is to certify that the PhD dissertation of Krystina Gerette Sorwell has been approved Henryk Urbanski Mentor/Advisor Steven Kohama Member Kathleen Grant Member Cynthia Bethea Member Deb Finn Member 1 For Lily 2 TABLE OF CONTENTS Acknowledgments ......................................................................................................................................................... 4 List of Figures and Tables ............................................................................................................................................. 7 List of Abbreviations ................................................................................................................................................... 10 Abstract........................................................................................................................................................................ 13 Introduction ................................................................................................................................................................. 15 Part A: Central steroidogenesis and cognition ............................................................................................................
    [Show full text]
  • Gene Expression Profile in Different Age Groups and Its Association With
    cells Article Gene Expression Profile in Different Age Groups and Its Association with Cognitive Function in Healthy Malay Adults in Malaysia Nur Fathiah Abdul Sani 1 , Ahmad Imran Zaydi Amir Hamzah 1, Zulzikry Hafiz Abu Bakar 1 , Yasmin Anum Mohd Yusof 2, Suzana Makpol 1 , Wan Zurinah Wan Ngah 1 and Hanafi Ahmad Damanhuri 1,* 1 Department of Biochemistry, Faculty of Medicine, Universiti Kebangsaan Malaysia Medical Center, Jalan Yaacob Latif, Cheras, Kuala Lumpur 56000, Malaysia; [email protected] (N.F.A.S.); [email protected] (A.I.Z.A.H.); zulzikryhafi[email protected] (Z.H.A.B.); [email protected] (S.M.); [email protected] (W.Z.W.N.) 2 Faculty of Medicine and Defence Health, National Defence University of Malaysia, Kem Sungai Besi, Kuala Lumpur 57000, Malaysia; [email protected] * Correspondence: hanafi[email protected] Abstract: The mechanism of cognitive aging at the molecular level is complex and not well under- stood. Growing evidence suggests that cognitive differences might also be caused by ethnicity. Thus, this study aims to determine the gene expression changes associated with age-related cognitive decline among Malay adults in Malaysia. A cross-sectional study was conducted on 160 healthy Malay subjects, aged between 28 and 79, and recruited around Selangor and Klang Valley, Malaysia. Citation: Abdul Sani, N.F.; Amir Gene expression analysis was performed using a HumanHT-12v4.0 Expression BeadChip microarray Hamzah, A.I.Z.; Abu Bakar, Z.H.; kit. The top 20 differentially expressed genes at p < 0.05 and fold change (FC) = 1.2 showed that Mohd Yusof, Y.A.; Makpol, S.; Wan PAFAH1B3, HIST1H1E, KCNA3, TM7SF2, RGS1, and TGFBRAP1 were regulated with increased Ngah, W.Z.; Damanhuri, H.A.
    [Show full text]
  • 07052020 MR ASCO20 Curtain Raiser
    Media Release New data at the ASCO20 Virtual Scientific Program reflects Roche’s commitment to accelerating progress in cancer care First clinical data from tiragolumab, Roche’s novel anti-TIGIT cancer immunotherapy, in combination with Tecentriq® (atezolizumab) in patients with PD-L1-positive metastatic non- small cell lung cancer (NSCLC) Updated overall survival data for Alecensa® (alectinib), in people living with anaplastic lymphoma kinase (ALK)-positive metastatic NSCLC Key highlights to be shared on Roche’s ASCO virtual newsroom, 29 May 2020, 08:00 CEST Basel, 7 May 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data from clinical trials of 19 approved and investigational medicines across 21 cancer types, will be presented at the ASCO20 Virtual Scientific Program organised by the American Society of Clinical Oncology (ASCO), which will be held 29-31 May, 2020. A total of 120 abstracts that include a Roche medicine will be presented at this year's meeting. "At ASCO, we will present new data from many investigational and approved medicines across our broad oncology portfolio," said Levi Garraway, M.D., Ph.D., Roche's Chief Medical Officer and Head of Global Product Development. “These efforts exemplify our long-standing commitment to improving outcomes for people with cancer, even during these unprecedented times. By integrating our medicines and diagnostics together with advanced insights and novel platforms, Roche is uniquely positioned to deliver the healthcare solutions of the future." Together with its partners, Roche is pioneering a comprehensive approach to cancer care, combining new diagnostics and treatments with innovative, integrated data and access solutions for approved medicines that will both personalise and transform the outcomes of people affected by this deadly disease.
    [Show full text]
  • Cogent Biosciences Announces Creation of Cogent Research Team
    Cogent Biosciences Announces Creation of Cogent Research Team April 6, 2021 Names industry veteran John Robinson, PhD as Chief Scientific Officer New Boulder-based team with exceptional track record of drug discovery and development focused on creating novel small molecule therapies for rare, genetically driven diseases Strong year-end cash position of $242.2 million supports company goals into 2024, including three CGT9486 clinical trials on-track to start this year, beginning with ASM in 1H21 BOULDER, Colo. and CAMBRIDGE, Mass., April 6, 2021 /PRNewswire/ -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the formation of the Cogent Research Team led by newly appointed Chief Scientific Officer, John Robinson, PhD. "Today marks an important step forward for Cogent Biosciences as we announce the formation of the Cogent Research Team with a focus on discovering and developing new small molecule therapies for patients fighting rare, genetically driven diseases," said Andrew Robbins, President and Chief Executive Officer of Cogent Biosciences. "I am thrilled to welcome John onboard as Cogent Biosciences' Chief Scientific Officer. John's expertise and seasoned leadership make him ideally suited to lead this new team of world class scientists. Given the team's impressive experience and accomplishments, we are excited for Cogent Biosciences' future and the opportunity to expand our pipeline and deliver novel precision therapies for patients." With an exceptional track record of innovation, the Cogent Research Team will focus on pioneering best-in-class, small molecule therapeutics to both improve upon existing drugs with clear limitations, as well as create new breakthroughs for diseases where others have been unable to find solutions.
    [Show full text]
  • Prior Authorization Oncology – Tukysa™ (Tucatinib Tablets)
    Cigna National Formulary Coverage Policy Prior Authorization Oncology – Tukysa™ (tucatinib tablets) Table of Contents Product Identifier(s) National Formulary Medical Necessity ................ 1 64724 Conditions Not Covered....................................... 2 Background .......................................................... 2 References .......................................................... 2 Revision History ................................................... 2 INSTRUCTIONS FOR USE The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients. Coverage Policies are intended to provide guidance in interpreting certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer’s particular benefit plan document [Group Service Agreement, Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard benefit plans upon which these Coverage Policies are based. For example, a customer’s benefit plan document may contain a specific exclusion related to a topic addressed in a Coverage Policy. In the event of a conflict, a customer’s benefit plan document always supersedes the information in the Coverage Policies. In the absence of a controlling federal or state coverage mandate, benefits are ultimately determined by the terms of the applicable benefit plan document. Coverage determinations in each specific instance require consideration of 1) the terms of the applicable benefit plan document in effect on the date of service; 2) any applicable laws/regulations; 3) any relevant collateral source materials including Coverage Policies and; 4) the specific facts of the particular situation.
    [Show full text]
  • Phase II Study of Selumetinib, an Orally Active Inhibitor of MEK1 and MEK2 Kinases, in KRASG12R-Mutant Pancreatic Ductal Adenocarcinoma
    UC Davis UC Davis Previously Published Works Title Phase II study of selumetinib, an orally active inhibitor of MEK1 and MEK2 kinases, in KRASG12R-mutant pancreatic ductal adenocarcinoma. Permalink https://escholarship.org/uc/item/3520819s Journal Investigational new drugs, 39(3) ISSN 0167-6997 Authors Kenney, Cara Kunst, Tricia Webb, Santhana et al. Publication Date 2021-06-01 DOI 10.1007/s10637-020-01044-8 Peer reviewed eScholarship.org Powered by the California Digital Library University of California Investigational New Drugs (2021) 39:821–828 https://doi.org/10.1007/s10637-020-01044-8 SHORT REPORT Phase II study of selumetinib, an orally active inhibitor of MEK1 and MEK2 kinases, in KRASG12R-mutant pancreatic ductal adenocarcinoma Cara Kenney1 & Tricia Kunst1 & Santhana Webb1 & Devisser Christina Jr2 & Christy Arrowood3 & Seth M. Steinberg4 & Niharika B. Mettu3 & Edward J. Kim2 & Udo Rudloff1,5 Received: 5 November 2020 /Accepted: 3 December 2020 / Published online: 6 January 2021 # This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply 2020 Summary Background Preclinical evidence has suggested that a subset of pancreatic cancers with the G12R mutational isoform of the KRAS oncogene is more sensitive to MAPK pathway blockade than pancreatic tumors with other KRAS isoforms. We con- ducted a biomarker-driven trial of selumetinib (KOSELUGO™; ARRY-142886), an orally active, allosteric mitogen-activated protein kinase 1 and 2 (MEK1/2) inhibitor, in pancreas cancer patients with somatic KRASG12R mutations. Methods In this two- stage, phase II study (NCT03040986) patients with advanced pancreas cancer harboring somatic KRASG12R variants who had received at least one standard-of-care systemic therapy regimen received 75 mg selumetinib orally twice a day until disease progression or unacceptable toxicity occurred.
    [Show full text]
  • Gabaergic Signaling Linked to Autophagy Enhances Host Protection Against Intracellular Bacterial Infections
    ARTICLE DOI: 10.1038/s41467-018-06487-5 OPEN GABAergic signaling linked to autophagy enhances host protection against intracellular bacterial infections Jin Kyung Kim1,2,3, Yi Sak Kim1,2,3, Hye-Mi Lee1,3, Hyo Sun Jin4, Chiranjivi Neupane 2,5, Sup Kim1,2,3, Sang-Hee Lee6, Jung-Joon Min7, Miwa Sasai8, Jae-Ho Jeong 9,10, Seong-Kyu Choe11, Jin-Man Kim12, Masahiro Yamamoto8, Hyon E. Choy 9,10, Jin Bong Park 2,5 & Eun-Kyeong Jo1,2,3 1234567890():,; Gamma-aminobutyric acid (GABA) is the principal inhibitory neurotransmitter in the brain; however, the roles of GABA in antimicrobial host defenses are largely unknown. Here we demonstrate that GABAergic activation enhances antimicrobial responses against intracel- lular bacterial infection. Intracellular bacterial infection decreases GABA levels in vitro in macrophages and in vivo in sera. Treatment of macrophages with GABA or GABAergic drugs promotes autophagy activation, enhances phagosomal maturation and antimicrobial responses against mycobacterial infection. In macrophages, the GABAergic defense is mediated via macrophage type A GABA receptor (GABAAR), intracellular calcium release, and the GABA type A receptor-associated protein-like 1 (GABARAPL1; an Atg8 homolog). Finally, GABAergic inhibition increases bacterial loads in mice and zebrafish in vivo, sug- gesting that the GABAergic defense plays an essential function in metazoan host defenses. Our study identified a previously unappreciated role for GABAergic signaling in linking antibacterial autophagy to enhance host innate defense against intracellular bacterial infection. 1 Department of Microbiology, Chungnam National University School of Medicine, Daejeon 35015, Korea. 2 Department of Medical Science, Chungnam National University School of Medicine, Daejeon 35015, Korea.
    [Show full text]
  • Insights from Drug Discovery Life Cycle Management in Pharmaceutical Industry: a Case-Study B
    et International Journal on Emerging Technologies 10 (4): 212-217(2019) ISSN No. (Print): 0975-8364 ISSN No. (Online): 2249-3255 Insights from Drug Discovery Life Cycle Management in Pharmaceutical Industry: A Case-study B. Thomas 1 and P. Chugan 2 1Research Scholar, Institute of Management, Nirma University, Ahmedabad (Gujarat), India. 2Professor (Retd.), Institute of Management, Nirma University, Ahmedabad (Gujarat), India. (Corresponding author: B. Thomas) (Received 20 September 2019, Revised 16 November 2019, Accepted 22 November 2019) (Published by Research Trend, Website: www.researchtrend.net) ABSTRACT: The Biotechnology and Pharmaceutical Industry has always stood up to the challenge of discovering innovative products fulfilling high unmet medical needs for mankind. The drug discovery and development pathway is very challenging and time consuming from efficacy, safety, regulatory and investments perspective. Hence, there is a significant need for collaboration among the biotechnology and large pharmaceutical companies to develop and commercialize their product innovations across the globe. This paper reviews the discovery and development of Selumetinib by Array Biopharma from year 2000 to 2019 when the USFDA accepted the first NDA filing for neurofibromatosis type one (NF1) disease. Array biopharma successfully developed several other drugs to the marketplace and several drugs to late stage registration trials either itself or in collaboration with strategic partners. These strategic partnerships helped mitigate risks in drug development and registration. This study of the clinical, regulatory and partnership strategy untaken for Selumetinib has created important contribution in the field of product life cycle management in the pharmaceutical and biotechnology industry. Keywords: Product development, drug development, life-cycle management, strategic partnership.
    [Show full text]
  • Patient Group Input Submissions
    CBCN’s 2012 Metastatic Breast Cancer Patient and Caregiver Survey Report: An online survey was distributed to patients living with metastatic breast cancer and their caregivers. No patients surveyed had experience with the treatment under review. Survey questions comprised of a combination of scoring options and free form commentary. Patients were contacted through the membership databases of CBCN and other patient organizations. -71 patients participated in the survey -16 caregivers participated in the survey Printed sources: A review was conducted of current studies and grey literature to identify issues and experiences that are commonly shared among many women living with metastatic breast cancer. 3. Disease Experience Metastatic breast cancer is the spread of cancerous cell growth to areas of the body other than where the cancer first formed. It is most commonly spread to the bones, but can include the lungs, liver, brain and skin. Triple-negative breast cancer (TNBC) is breast cancer that is estrogen-receptor-negative, progesterone-receptor-negative and HER2-negative. Accounting for 12-17% of breast cancers, TNBC’s have been shown to be relatively aggressive and display a high risk of metastasis and death within 5 years after diagnosis. TNBC is considered to be vastly heterogeneous and is often used as an umbrella term, encompassing a wide spectrum of entities with marked genetic, transcriptional, histological, and clinical differences. 1 A rare cancer that is more commonly associated with TNBC, is secretory breast carcinomas- a cancer that occurs due to an over secretion of mucin in the tumor. It is considered a subtype of invasive ductal carcinoma but is prone to metastasis and local recurrence.
    [Show full text]
  • Characterisation of GABAA Receptors and Cation-Chloride Cotransporters in the Uterus and Their Role in Pre-Term Labour
    Characterisation of GABAA receptors and cation-chloride cotransporters in the uterus and their role in pre-term labour Melissa Linda Sutherland December 2017 Supervisors: Dr. Amy V. Poole, Dr. Jennifer A. Fraser, Dr. Claire Garden. A thesis submitted in partial fulfilment of the requirements of Edinburgh Napier University, for the award of Master by Research Declaration It is hereby declared that this thesis is the result of the author’s original research. It has been composed by the author and has not been previously submitted for examination, which has led to the award of a degree or professional qualification. Signed: Date: Contents page Abbreviations .............................................................................................. 1 Acknowledgements ................................................................................... 3 Abstract ......................................................................................................... 4 CHAPTER 1. Introduction ......................................................................... 5 1.1-aminobutyric acid (GABA) .............................................................. 5 1.2 GABA receptor structure and function .......................................... 5 Figure 1.1 Schematic diagram of the GABAA subunit and receptor ......................................................................................................... 6 1.3 GABAARs role in development central nervous system ..........................................................................................................
    [Show full text]